Jane M Shiah from 22805 Chardonnay Dr, Pomona, CA 91765, age 67

Kinase Inhibitors
view source
US Patent:

8143410, Mar 27, 2012
Filed:

Jan 5, 2009
Appl. No.:

12/319356
Inventors:

Lon T. Spada - Walnut CA, US
Jane Guo Shiah - Irvine CA, US
Patrick Hughes - Aliso Viejo CA, US
Thomas C. Malone - Irvine CA, US
Gerald W. Devries - San Clemente CA, US
Jeffrey L. Edelman - Irvine CA, US
Julie A. Wurster - Irvine CA, US
Assignee:

Allergan, Inc. - Irvine CA
International Classification:

C07D 211/72
C07D 241/00
A61K 31/50
A61K 31/44
US Classification:

546316, 544336, 514248, 514344
Abstract:

The present invention relates to drug delivery systems comprising ocular implant, which include organic molecules, capable of modulating tyrosine kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell proliferation, in combination with a polymer, which polymer serves to control, modify, modulate and/or slow the release of the therapeutic component into the environment of the eye in which said composite is placed.

Kinase Inhibitors
view source
US Patent:

8383825, Feb 26, 2013
Filed:

Jul 7, 2011
Appl. No.:

13/178277
Inventors:

Lon T. Spada - Walnut CA, US
Jane Guo Shiah - Irvine CA, US
Patrick Hughes - Aliso Viejo CA, US
Thomas C. Malone - Irvine CA, US
Gerald W. Devries - San Clemente CA, US
Jeffrey L. Edelman - Irvine CA, US
Julie A. Wurster - Irvine CA, US
Assignee:

Allergan, Inc. - Irvine CA
International Classification:

C07D 211/72
A61K 31/44
A61K 31/50
US Classification:

546290, 544346, 514248, 514344
Abstract:

The present invention relates to drug delivery systems comprising ocular implant, which include organic molecules, capable of modulating tyrosine kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell proliferation, in combination with a polymer, which polymer serves to control, modify, modulate and/or slow the release of the therapeutic component into the environment of the eye in which said composite is placed.

Kinase Inhibitors
view source
US Patent:

8455656, Jun 4, 2013
Filed:

Feb 26, 2009
Appl. No.:

12/380493
Inventors:

Lon T. Spada - Walnut CA, US
Jane Guo Shiah - Irvine CA, US
Patrick Hughes - Aliso Viejo CA, US
Thomas C. Malone - Irvine CA, US
Gerald W. Devries - San Clemente CA, US
Jeffrey L. Edelman - Irvine CA, US
Julie A. Wurster - Irvine CA, US
Xialing Guo - San Clemente CA, US
Sougato Boral - Santa Ana CA, US
Assignee:

Allergan, Inc. - Irvine CA
International Classification:

A61K 31/40
A61F 9/007
C07D 213/00
US Classification:

546339, 514414, 604 8
Abstract:

The present invention relates to drug delivery systems comprising ocular implant, which include organic molecules, capable of modulating tyrosine kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell proliferation, in combination with a polymer, which polymer serves to control, modify, modulate and/or slow the release of the therapeutic component into the environment of the eye in which said composite is placed.

Biodegradable Intravitreal Tyrosine Kinase Implants
view source
US Patent:

8512738, Aug 20, 2013
Filed:

Apr 29, 2005
Appl. No.:

11/119001
Inventors:

Jeffrey L. Edelman - Irvine CA, US
Patrick M. Hughes - Aliso Viejo CA, US
Thomas C. Malone - Irvine CA, US
Gerald W. De Vries - Laguna Hills CA, US
Jane Guo Shiah - Irvine CA, US
Thierry Nivaggioli - Irvine CA, US
Lon T. Spada - Walnut CA, US
Wendy M. Blanda - Tustin CA, US
Assignee:

Allergan, Inc. - Irvine CA
International Classification:

A61F 2/14
US Classification:

424428
Abstract:

Biocompatible intraocular implants include a tyrosine kinase inhibitor and a biodegradable polymer that is effective to facilitate release of the tyrosine kinase inhibitor into the vitreous of an eye for an extended period of time. The therapeutic agents of the implants may be associated with a biodegradable polymer matrix, such as a matrix that is substantially free of a polyvinyl alcohol. The implants can be placed in an eye to treat or reduce the occurrence of one or more ocular conditions, such as posterior ocular conditions.

Extended Release Biodegradable Ocular Implants
view source
US Patent:

20050244467, Nov 3, 2005
Filed:

Apr 30, 2004
Appl. No.:

10/837355
Inventors:

Thierry Nivaggioli - Los Altos CA, US
Jane Shiah - Cupertino CA, US
Qing Lin - Fremont CA, US
Assignee:

ALLERGAN, INC. - Irvine CA
International Classification:

A61F013/00
US Classification:

424427000
Abstract:

Biodegradable implants sized and suitable for implantation in an ocular region or site and methods for treating ocular conditions. The implants provide an extended release of an active agent at a therapeutically effective amount for a period of time between 50 days and one year, or longer.

Estradiol Derivative And Estratopone Containing Sustained Release Intraocular Implants And Related Methods
view source
US Patent:

20050244471, Nov 3, 2005
Filed:

Apr 30, 2004
Appl. No.:

10/837379
Inventors:

Jane Guo Shiah - Cupertino CA, US
Paul Dickinson - Saratoga CA, US
Assignee:

Allergan, Inc. - Irvine CA
International Classification:

A61K031/69
A61K031/56
A61F002/00
US Classification:

424427000, 514064000, 514182000
Abstract:

Biocompatible intraocular implants include an anti-angiogenic agent, such as estradiol derivative or an estratopone and a biodegradable polymer that is effective to facilitate release of the anti-angiogenic agent into an eye for an extended period of time. The therapeutic agents of the implants may be associated with a biodegradable polymer matrix, such as a matrix that is substantially free of a polyvinyl alcohol. The implants may be placed in an eye to treat or reduce the occurrence of one or more ocular conditions, such as angiogenisis, ocular tumors, and the like.

Extended Release Biodegradable Ocular Implants
view source
US Patent:

20080241223, Oct 2, 2008
Filed:

May 1, 2008
Appl. No.:

12/113434
Inventors:

Thierry NIVAGGIOLI - Los Altos Hills CA, US
Jane Guo Shiah - Cupertino CA, US
Qing Lin - Fremont CA, US
Assignee:

ALLERGAN, INC. - Irvine CA
International Classification:

A61F 2/00
A61K 31/56
A61P 27/02
US Classification:

424428, 424427, 514180
Abstract:

Biodegradable implants sized and suitable for implantation in an ocular region or site and methods for treating ocular conditions. The implants provide an extended release of an active agent at a therapeutically effective amount for a period of time between 50 days and one year, or longer.

Kinase Inhibitors
view source
US Patent:

20090208557, Aug 20, 2009
Filed:

Dec 23, 2008
Appl. No.:

12/317469
Inventors:

Lon T. Spada - Walnut CA, US
Jane Guo Shiah - Irvine CA, US
Patrick Hughes - Aliso Viejo CA, US
Thomas C. Malone - Irvine CA, US
Gerald W. DeVries - San Clemente CA, US
Jeffrey L. Edelman - Irvine CA, US
Julie A. Wurster - Irvine CA, US
Wendy M. Blanda - Tustin CA, US
International Classification:

A61F 2/00
A61K 31/403
A61K 31/4965
A61K 31/4427
A61K 31/53
US Classification:

424428, 514418, 51425505, 514339, 514241
Abstract:

The present invention relates to drug delivery systems comprising ocular implant, which include organic molecules, capable of modulating tyrosine kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell proliferation, in combination with a polymer, which polymer serves to control, modify, modulate and/or slow the release of the therapeutic component into the environment of the eye in which said composite is placed.

Jane M Shiah